Loading
A phase 2 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07700667 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500, Tislelizumab, Cisplatin and 5 - FU.
Shares Oesophageal squamous cell carcinoma, Tislelizumab, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Sichuan Kelun-Biotech, Tislelizumab and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Tislelizumab, Cisplatin and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.